0 CHECKOUT

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015

  • ID: 3446773
  • September 2015
  • 63 pages
  • Global Markets Direct
1 of 3

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015

Summary

The report ‘Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview

Therapeutics Development

Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Overview

Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Development by Companies

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Products Glance

Early Stage Products

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Development by Companies

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Investigation by Universities/Institutes

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Companies Involved in Therapeutics Development

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Kineta, Inc.

Myelo Therapeutics GmbH

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CEL-1000 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

D-3252 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IKT-014 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LCA-60 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ML-188 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MMCatLMC - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for SARS Virus Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myelo-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rOAS - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SARS vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SARS vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SARS-CoV Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

severe acute respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

severe acute respiratory syndrome vaccine + middle east respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for SARS - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SSYA-10001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide to Target Spike Protein for SARS Infection - Drug Profile

Product Description

Mechanism of Action

R&D Progress

thiocarbazate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Recent Pipeline Updates

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Product Development Milestones

Featured News & Press Releases

May 19, 2014: Kineta’s Novel Antiviral Drugs Show Encouraging Efficacy Against Dengue And SARS Viruses

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H2 2015

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by CEL-SCI Corporation, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by GeneCure LLC, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Humabs BioMed SA, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Kineta, Inc., H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Myelo Therapeutics GmbH, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Nanotherapeutics, Inc., H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Novavax, Inc., H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Protein Sciences Corporation, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Recent Pipeline Updates, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects (Contd..1), H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H2 2015

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.